FindTrial
Sign In

Evaluation for effect of early use of Toramyxin extracorporeal hemoperfusion cartridge (PMX) as adjuvant therapy in secondary peritonitis patients with persistent septic shock after laparotomy

Efficacy of Postoperative Polymyxin B Hemoperfusion (PMX) on The Treatment for Secondary Peritonitis Patient with Septic Shock: A Propensity-Matched Analysis of Single Institute Experience

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16008160
Enrollment
Unknown
Registered
2016-03-27
Start date
1990-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SEPSIS WITH SEPTIC SHOCK

Interventions

STUDY GROUP:Toramyxin extracorporeal hemoperfusion cartridge (PMX)

Sponsors

Chang Gung Memorial Hospital, Linkou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
86 Years to 31 Years

Inclusion criteria

Inclusion criteria: 1. secondary peritonitis; 2. received laparotomy; 3. admitted to ICU after operation; 4. sustained septic shock status after operation (need to use vasopressor or inotropic agent use to maintain mean artery pressure > 90mmHg).

Exclusion criteria

Exclusion criteria: 1. 2; 9. need to receive CVVHD in ICU.

Design outcomes

Primary

MeasureTime frame
PATIENT SURVIVAL;—

Countries

China

Contacts

Public ContactKUO-CHING YUAN

Chang Gung Memorial Hospital, Linkou

traumayuan@gmail.com+886 939930566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 11, 2026